Company Overview
About Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.
Business Model & Competitive Advantage
Tempus went public on Nasdaq in June 2024 under the ticker symbol TEM, making its capital markets debut as one of the most anticipated healthcare AI IPOs of the year. In full-year 2025, Tempus reported revenue of $1.27B, an 83% increase from $693M in 2024, and achieved a record total contract value exceeding $1.1 billion. The company's market capitalization exceeds $14B, and Tempus stock rose 87% in 2025. Tempus provides 2026 revenue guidance of approximately $1.59B, representing ~25% growth. The company's genomics segment (lab testing revenue) and data and services segment (AI-powered analytics and pharma partnerships) both contribute to the top line, with the data segment expanding rapidly as pharmaceutical companies license Tempus's multimodal dataset for drug development applications.
Competitive Landscape 2025–2026
Tempus's competitive moat rests on the scale and quality of its proprietary dataset — covering millions of de-identified patient records with linked clinical, genomic, imaging, and outcomes data. This dataset, continuously enriched through clinical partnerships with health systems nationwide, underpins AI model training that competitors cannot easily replicate. Tempus competes with Foundation Medicine (Roche), Guardant Health, and NeoGenomics in genomic profiling, and with Flatiron Health (Roche) in real-world data for pharma, but its integrated AI platform spanning multiple disease areas differentiates its offering.
Key Differentiators
Market Leader
Tempus is recognized as a market leader in the Life Sciences & BioTech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $1.27B in revenue, Tempus operates at enterprise scale with proven market validation.
Frequently Asked Questions
Similar Brands
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Compare Tempus with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Tempus? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Tempus Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Tempus vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →